Accurate costing is not possible, and a crude figure for our reading a smear is £0-50. For the past three years, we have been field testing the Vickers Screening Apparatus. Costs will be cut considerably if we can satisfy ourselves that it fulfils its function of helping us sieve out abnormal smears. Under these circumstances, the cervical smear should play a similar role for the clinician as blood film examination must have done in the days when addisonian anemia was considered a fatal disease. The evidence suggests that the clinician cannot do without this test and that it obeys Sydenham's rule that 'what is useful is good'.
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Effects of Screening Programmes on Laboratory Organization
One of the main effects of screening programmes may well be that laboratories will have to develop an impersonal attitude towards the investigations sent to a centralized laboratory, and will lose the close and personal relationships which have now developed between pathologists and their clinical colleagues.
A new philosophy is required and it is not easy for any present-day laboratory organization to jump into screening without comprehending this philosophy. Most clinicians are brought up to accept a time-table of laboratory processing which is geared to speedy diagnosis, so that therapeutic adjustments may be quickly instituted. Emergency services which have to be maintained throughout 24 hours are also essential so that quick answers may be obtained at any hour of the day or night if they are justified.
In theory, screening programmes are certainly not urgent, yet there has to be some degree of urgency in the carrying out of the tests once they arrive in the laboratory. This is because the machines have to be kept going and the results churned out, or the whole system will get blocked with the large amount of material waiting to be processed.
Automation must not be confused with screening. Anybody undertaking screening will have to introduce automation; it could hardly be done without. But automation is already required and is almost essential in most laboratories for reasons already well describedability to deal with the greatly increasing volume of requests, the reduction of the cost per test, speed and accuracy due to better built-in quality control. Immediately automation is introduced, the potential of the laboratory will be greatly increased and a bottleneck occurs unless data processing is added. From this it is a small step to the demand for profile screening and, later perhaps, population screening. Automation itself usually means that 12 or 15 results can be supplied from one sample of blood. Then, as so many people have said, it is easier to do all 15 tests than to sort out one or two channels for special investigation. In fact, most systems are so inelastic that you have to have the whole output. Many laboratories are now geared to multi-channel biochemistry and hematology for their routine investigation of both inpatients and outpatients.
The effect on clinicians is bad, Every time a doctor asks for a blood urea he will get back 15 results, and he will soon be demanding indiscriminately all the 15 investigations. Even if 15 tests are needed for proffles they are certinly not necessary for repeat and up-dating of results.
Screening (Single Investigations)
Phenylketonuria: Most authorities have centralized this investigation into one laboratory in each region; material is sent there, special staff is engaged, special areas of the laboratory are designated, recording and statistical analysis are provided so that the whole picture in a region can be assessed. With an incidence of one positive per 15,000 tests, Professor Whitehead estimates that each positive finding costs about £1,000. This must be set against the cost to the community of institutional care for an undetected affected child for life. We are not very far from full amino-acid deficiency screening on the same lines. Vaginal cytology: The effect of this screening procedure is very variable. Dr Levene has described a regional service: however, most area laboratories have screening facilities for vaginal cytology, and much useful information has been obtained on the natural history of carcinoma of the cervix. Perhaps we shall feel the money has been well spent when carcinoma of the cervix shows some signs of a fall in incidence.
Profile Screening Dr Carmalt has spoken of the value of this technique and the sorting and follow up of results which show more than ±2 s.d. for more detailed investigation (see p 1257). It is only a step from this to a population screening; you merely have to double the size of the laboratory to undertake a population screening programme. In Chelsea and Kensington, with a population of 300,000 and a laboratory which has a programme to cover hospital requirements for automated computerized chemistry and further automation shortly to be extended to heematology, to add full hospital profile and population screening would mean adding at least a further 100,000 specimens per year. Without taking account of the repetition of doubtful results, the requirements would approximate to a 100 % increase in the present automated computerized equipment, assuming that it will work for 15 hours per day for 50 weeks in the year (M G Rinsler, personal communication).
Automation and screening have highlighted one or two other aspects of laboratory organization:
Patient recognition: It is essential that a standard simple method of patient identification be introduced. If population screening is envisaged we must persuade all the authorities that something like the patient's NHS number be used, possibly both in and out of hospital.
Collection of specimens: A major organization is needed to reach GPs in health centres and other places where specimens will be collected. Hospitals already have to employ blood collectors for the ordinary investigation of their patients. These teams will have to be on a much bigger scale, with perhaps a special staff on the lines of a mobile blood transfusion team. In the Varmland Project in Sweden 88,881 people were screened in three years and about 5 % were found to have early unknown disease. At the International Conference in Elsinore in 1966, it was suggested that it would be more economical if higher speeds of analysis were available, e.g. a rate of 150 tests per hour compared with our now conventional 40-60, and an increased range of tests from the 12 or 15 now available to 40. Out of these recommendations there has grown the Auto Chemist which I believe weighs about 4 tons.
Mechanical handling of reagents: Not only the specimens and the computerized output of results must be mechanized, but also the reagents because they are becoming so bulky that special storage space must be made available and the reagents may have to be pumped from large vats in a basement to the relevant points on the analysers, rather like a brewery.
Finally, the effect on staff: I would not like to condemn anybody to testing for phenylketonuria as a job for life, nor would I advise anybody to become a cyto screener for life. You certainly would not get an intake of the best scientific or technological people if their goal were to be attending large Auto Chemists for life. If, however, we can arrange screening programmes so that technologists and scientists could rotate from the factory type of population-screening laboratory to an automation laboratory for hospital clinical pathology, and then to the acute laboratory for hand methods demanding personal chemical skills from the technologists, then the profession might survive the inroads which will certainly be made into it by manufacturers and other commercial interests. The pathologist or senior scientific officer must maintain a personal and intimate contact with the clinicians with whom he has to work so that the results are meaningful to both.
The following paper was also read: Meeting June 231971 A laboratory meeting was held in the Harkness Laboratory, Radcliffe Infirmary, Oxford. Demonstrations were given and papers read.
